A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)

Mathias J. Rummel,1 Ann Janssens,2,* David MacDonald,3 Mary-Margaret Keating,3 Jan M. Zaucha,4 Jaclyn Davis,5 Janet Lasher,7 Chaitali Babanrao Pisal,6 Miguel Izquierdo7 and Jonathan W. Friedberg8
1Department for Haematology, Clinic for Haematology and Medical Oncology, Justus-Liebig University-Hospital, Gießen, Germany, 2Department of Haematology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 3Division of Haematology, Dalhousie University, Halifax, NS, Canada, 4Department of Haematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland, 5Novartis Oncology, East Hanover, NJ, USA, 6Novartis Healthcare Pvt. Ltd., Hyderabad, India, 7Novartis Pharma AG, Basel, Switzerland, and 8Wilmot Cancer Institute, University of Rochester Medical Centre, Rochester, NY, USA

Received 17 November 2020; accepted for publication 28 February 2021
Correspondence: Mathias Rummel,
Department for Haematology, Clinic for Haematology and Medical Oncology, Justus-Liebig University-Hospital, Gießen, Germany.
E-mail: mathias.rummel@innere.med.uni-giessen.de
*Present address: Division of Haematology, University of Ottawa, Ottawa, ON, Canada.

Summary
The standard of care for indolent non-Hodgkin lymphoma (iNHL) is rituximab, an anti-CD20 antibody, with/without chemotherapy. However, multiple relapses are common in these patients. This phase 3, randomized study compared outcomes of a combination of ofatumumab (a second-generation anti-CD20 antibody) and bendamustine, with bendamustine alone in patients unresponsive to prior rituximab-based treatment. Overall, 346 patients were randomized to receive either the combination or bendamustine alone. Bendamustine was given for ≤8 cycles and ofatumumab for ≤12 cycles. The primary end-point was progression-free survival (PFS) after 215 protocol-defined events assessed by independent review committee (IRC). Median IRC-assessed PFS was 16.7 and 13.8 months in the combination and monotherapy arms respectively [hazard ratio (HR) = 0.82; P = 0.1390]. Median overall survival (OS) was 58.2 and 51.8 months in the combination and monotherapy arms respectively (HR = 0.89, P = 0.4968). The safety profile was consistent with previous reports. Overall, 73% and 80% of patients in the combination and monotherapy arms, respectively, experienced a ≥ grade 3 adverse event. The study did not meet its primary end-point. No significant improvement in PFS and OS was seen with the combination of ofatumumab and bendamustine as compared with bendamustine alone in rituximab-refractory iNHL (NCT01077518).

Keywords: anti-CD20, ofatumumab, rituximab, bendamustine, rituximab-refractory indolent non-Hodgkin lymphoma.

Introduction
Non-Hodgkin lymphoma (NHL) is one of the most common haematologic malignancies worldwide, with an estimated 77 240 new cases and 19 940 deaths in 2020 in the USA.1,2 Indolent NHL (iNHL) is a heterogeneous subgroup that accounts for almost 40% of NHL cases, of which follicular lymphoma (FL) is the most common.3,4 Despite the many treatment options available for the majority of patients, iNHL remains an incurable disease. Since the introduction of rituximab, improved outcomes in subjects with iNHL have been observed.5,6 Rituximab has been shown to be effective as a single agent,7 and also to improve progression-free (PFS) and overall survival (OS)
when given in combination with chemotherapy regimens including cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), cyclophosphamide, vincristine and prednisone (R-CVP), fludarabine, and bendamustine to patients with previously untreated and relapsed/refractory iNHL. Based on encouraging results observed in multiple clinical trials, rituximab-based chemo-immunotherapy has become the standard of care for patients with advanced-stage, high tumour burden iNHL.

Despite favourable up-front response rates with rituximab in combination with chemotherapy, multiple relapses with progressively shorter remission periods are common, and the disease may eventually become unresponsive to rituximab-based treatment. Approximately 20% of patients experience progression within two years of inducing chemo-immunotherapy have poor OS, and have been prioritized for clinical trials by the US National Clinical Trials Network. Due to repeated exposure to rituximab, the risk for acquired resistance increases, and there is an unmet medical need for an effective and safe therapeutic option for this patient population. Although, stem cell transplantation is a potential curative option, the challenges and risks involved with transplantation limit its use in elderly patients with comorbidities.

Bendamustine is approved in the USA and Europe for the treatment of iNHL that has progressed during or within six months of treatment with rituximab or rituximab-containing regimen. Rituximab in combination with bendamustine is established in the treatment of front-line and relapsed/refractory iNHL. Ofatumumab is a type I human monoclonal antibody (mAb) that binds to an epitope on the small and large loops of CD20, which is distinct from the binding site of rituximab. Single-agent ofatumumab has been approved for the treatment of fludarabine and alemtuzumab-refractory chronic lymphocytic leukaemia (CLL) and has shown positive results in the maintenance setting after at least two lines of treatment, in combination with cyclophosphamide and fludarabine for relapsed CLL, and in combination with chlorambucil for up-front treatment of patients with CLL deemed unfit for fludarabine. Previous phase 1/2 and phase 3 trials of ofatumumab have demonstrated clinical activity in patients with relapsed/refractory iNHL with an acceptable safety profile.

The complement A+B study evaluated the hypothesis that the addition of ofatumumab to bendamustine might provide additional clinical benefit to patients with iNHL who had failed to respond or progressed following rituximab-containing regimen.

Methods

Study design and patient population

COMPLEMENT A+B was a phase 3, open-label, randomized, multicentre, international study. Patients at least 18 years of age with CD20+ iNHL, which included small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma and Grades 1–3A FL based on the World Health Organization guidelines, were eligible for the study. Enrolled patients were unresponsive to rituximab, which was defined as either stable disease (SD) after or progressive disease (PD) during or within six months of rituximab-containing treatment. Patients had an Eastern Cooperative Oncology Group performance status of 0–2 and a life expectancy of ≥6 months. Key exclusion criteria included prior autologous or allogeneic stem cell transplant in the past six months; treatment with any monoclonal antibody (mAb; other than anti-CD20) within three months of randomization; treatment with bendamustine within the past one year not resulting in at least a partial response (PR) lasting for ≥6 months; chronic or current active infectious disease; clinically significant cardiac, cerebrovascular, hepatic disease; and/or screening laboratory abnormalities [neutrophils < 1.5 × 10⁹/l, platelets < 100 × 10⁹/l, creatinine > 1.5 times upper limit of normal (ULN), total bilirubin > 1.5 times ULN, and/or transaminases > 2 times ULN]. All patients were required to provide written informed consent to participate in the study.

Patients were stratified based on prior exposure to bendamustine and the type of prior rituximab therapy (monotherapy or in combination with chemotherapy), and were subsequently randomized 1:1 to receive either the combination of ofatumumab and bendamustine or bendamustine alone. Bendamustine (90 mg/m² in the combination arm and 120 mg/m² in the monotherapy arm) was given for up to eight cycles on days 1 and 2, every 21 days. In the combination arm, ofatumumab (1 000 mg) was given on day 1 of each cycle of bendamustine until eight cycles and subsequently every 28 days until 12 doses were completed. The decision to add four additional treatments with ofatumumab following completion of combination cycles was based on data with rituximab demonstrating enhanced response with prolonged administration as well as the data from the CLL Study NCT00349349. For patients in the bendamustine arm, if deemed appropriate by the investigator, ofatumumab monotherapy was allowed within 120 days of independent review committee (IRC)-confirmed PD. In these patients, 1 000 mg of ofatumumab was given, followed by 2 000 mg once a week for three weeks and then 2 000 mg monthly for eight months. The study was conducted in accordance with Good Clinical Practice guidelines and the guiding principles of the Declaration of Helsinki. The protocol was reviewed by an Independent Review Board at each participating Centre (clinicaltrials.gov identifier NCT010 77518).

Study assessments

The primary end-point was progression-free survival (PFS), defined as the time interval from randomization until disease
progression or death as per IRC. The secondary end-points were PFS in patients with FL, overall response rate (ORR), time to response (TTR), duration of response, time to progression and time to next therapy in all patients and in patients with FL.

The response assessments, complete response (CR), PR, SD and PD, were based on criteria defined in the Revised Response Criteria for Malignant Lymphoma guidelines. Lymphoma symptoms and contrast-enhanced computed tomography scans of the thorax, abdomen and pelvis (and neck, if palpable disease at baseline) were used to determine response assessments on days 84, 168 and 252, then quarterly until 18 months and yearly until 54 months. A repeat bone marrow examination to confirm CR was required within eight weeks from onset of CR if there was disease involvement in the bone marrow at baseline. All adverse events (AEs) and serious AEs (SAEs), regardless of the relationship to study drug, were collected from the first dose of treatment until 60 days after the last treatment. SAEs continued to be reported from 61 days after the last dose until the end of the follow-up period or until subsequent anti-lymphoma therapy initiated.

Statistical analysis

Interim and futility analyses and Independent Data Monitoring Committee (IDMC) review were performed when approximately two-thirds (or 180) of the initial total 259 IRC events had occurred. Due to the length of the study, the drop-out rate was higher than the protocol assumed (21% vs 12% respectively). As such, the protocol was amended to revise the number of PFS events required for the primary analysis to approximately 215. Since, during the interim analysis, 180 PFS events were observed by the IRC, the final boundary for PFS in terms of the P value scale was calculated as a two-sided 0.0482 using EAST v6.4. The secondary end-points, PFS in patients with FL, ORR and OS in all patients and in patients with FL were to be tested sequentially only if the previous end-point was statistically significant. Survival distributions were estimated using the Kaplan–Meier (KM) curves, which were compared using a stratified log-rank test. Analytical results included estimation of HRs along with 95% confidence intervals (CIs) and associated probabilities for the effect of treatment, stratification factors and the covariates.

Results

Patients

Between September 2010 and May 2016, 346 patients were enrolled and randomized at 85 centres across 15 countries. Of these patients, 43% (n = 149) received rituximab monotherapy as their qualifying treatment regimen and 57% (n = 197) received rituximab in combination with chemotherapy. The median number of prior rituximab-containing regimens was 1 and only 10% of patients (n = 33) enrolled on the study had prior exposure to bendamustine. The baseline characteristics were well-balanced between the two arms (Table 1). The median age of patients was 62 years; 59% were males; and 67% of patients had FL, 14% SLL and 11% MZL at initial diagnosis. Ann Arbor staging IV was common and reported for 65% of patients.

Patient disposition

The median treatment duration was 260 (1–367) days with combination and 135 (2–250) days with bendamustine. After a median duration of follow-up of 61-1 months, 58% and 65% of patients completed treatment with ofatumumab and bendamustine, respectively, in the combination arm, whereas 43% completed treatment in the bendamustine arm (Fig 1). Thirty patients in the bendamustine arm were treated in the optional ofatumumab arm after disease progression. In the combination arm, 94%, 81% and 59% completed three, six and 12 cycles of treatment, respectively, whereas with monotherapy, 91% and 65% completed three and six cycles respectively. Seventeen percent of patients in the ofatumumab and bendamustine arm and 10% of patients in the bendamustine arm discontinued the study treatment due to disease progression. Adverse events were the main reason for premature discontinuation for all treatments in the study.

Efficacy

The primary end-point of efficacy, PFS, was conducted after 217 PFS events as assessed by an IRC were reached. The primary end-point, analyzed using a log-rank test stratified by the type of last prior rituximab therapy and prior exposure to bendamustine, was not statistically significantly different between the treatment arms (P = 0.1390, 2-sided). There were 105 (61%) and 112 (65%) PFS events in the combination and monotherapy arms respectively. The median PFS was 16.7 months with ofatumumab and bendamustine vs 13.8 months with bendamustine [HR 0.82 (95% CI 0.62, 1.07; Fig 2A)]. The estimated PFS rates at 12 months were 59.6% and 55.1% for the combination and monotherapy arms respectively.

The secondary end-points for the study were not tested, as the primary end-point was not statistically significant. In the subset of patients with FL, there were 73 (61%) events in the combination arm with a median PFS of 16-6 months, and 75 (63%) events in the monotherapy arm with a median PFS of 12-1 months [HR 0.76 (95% CI 0.55, 1.06; Fig 2B)]. In this subset, the estimated PFS rates at 12 months were 60-1% and 50-8% for the combination and monotherapy arms respectively. Within 24 months, 51% and 58% of patients progressed in the combination and monotherapy arms respectively. The subgroup results were consistent with observations from the overall population as demonstrated by the
The exceptions were age 65 years (n = 195, HR = 0.64, 95% CIs: 0.45, 0.92) and low FLIPI-1 scores (n = 193, HR = 0.68, 95% CIs: 0.46, 0.98; Fig 3).

The IRC-assessed ORR was similar in both arms. With combination, the ORR (95% CI) was 73% (66%, 80%), with 21% of patients achieving CR, 53% PR and 13% SD. With bendamustine monotherapy, the ORR (95% CI) was 75% (67%, 81%), with 17% achieving CR, 58% PR and 9% SD. There was a difference in ORR of −1.2% (−10.4%, 8.1%) between the two arms. Similar results were observed in patients with FL. The ORR in the combination and monotherapy arms was 77% (68%, 84%) and 76% (67%, 83%), respectively, with a difference in ORR of 1.0% (−9.8%, 11.8%). In these patients, 24% had CR, 53% had PR and 12% had SD with the combination, while in the monotherapy arm, 20% had CR, 55% had PR and 6% had SD. For the 30 patients in the bendamustine arm who received optional ofatumumab following disease progression, the ORR at one month was 17% (6%, 35%). There was no difference in the KM estimates of TTR in either treatment arm, in all patients or in patients with FL [2.9 months each, 95% CI (2.8, 2.9)]. The KM estimates of the duration of response (DOR, 95% CI) for all patients were 17.9 months vs 51.8 months in the combination and monotherapy respectively [HR 0.69, 95% CI (0.63, 1.25); P = 0.04968; Fig 4A, B]. The frequencies of deaths and on-treatment deaths were similar in both arms. Overall, 38% of patients died in the combination arm, of which 7% were on-treatment deaths. Among patients treated with bendamustine, 41% died, with 9% on-treatment deaths. The main cause of death was the primary disease for both on-treatment

| Parameter                              | Ofatumumab + bendamustine | Bendamustine | Total |
|----------------------------------------|---------------------------|--------------|-------|
| Age (years), n (%)                     | (n = 171)                 | (n = 171)    | (n = 342) |
| 18–64                                  | 94 (55)                   | 100 (58)     | 194 (57) |
| 65–74                                  | 52 (30)                   | 46 (27)      | 98 (29)  |
| ≥75                                    | 25 (15)                   | 25 (15)      | 50 (15)  |
| Median (min, max)                      | 63 (29, 83)               | 62 (21, 87)  | 62 (21, 87) |
| Sex, n (%)                             | n = 172                   | n = 174      | n = 346  |
| Female                                 | 70 (41)                   | 73 (42)      | 143 (41) |
| Male                                   | 102 (59)                  | 101 (58)     | 203 (59) |
| Ethnicity, n (%)                       | n = 172                   | n = 174      | n = 346  |
| Hispanic or Latino                     | 5 (3)                     | 11 (6)       | 16 (5)   |
| Others                                 | 167 (97)                  | 163 (94)     | 330 (95) |
| Histology at initial diagnosis, n (%)  | n = 173                   | n = 173      | n = 346  |
| FL                                      | 118 (68)                  | 115 (66)     | 233 (67) |
| SLL                                     | 28 (16)                   | 21 (12)      | 49 (14)  |
| MZL                                     | 19 (11)                   | 18 (10)      | 37 (11)  |
| Others                                  | 8 (5)                     | 18 (10)      | 26 (8)   |
| Ann arbor staging at screening, n (%)   | n = 173                   | n = 173      | n = 346  |
| I                                       | 10 (6)                    | 4 (2)        | 14 (4)   |
| II                                      | 17 (10)                   | 26 (10)      | 33 (9)   |
| III                                     | 30 (17)                   | 40 (23)      | 70 (20)  |
| IV                                      | 113 (65)                  | 110 (64)     | 223 (65) |
| Missing                                 | 3 (2)                     | 3 (2)        | 6 (2)    |
| Number of prior rituximab therapies median (min, max) | 1 (1, 6) | 2 (1, 9) | 1 (1, 9) |
| Prior anti-cancer therapies, n (%)†    | n = 172                   | n = 174      | n = 346  |
| Fludarabine-based                       | 14 (8)                    | 11 (6)       | 25 (7)   |
| Bendamustine-based                      | 10 (6)                    | 13 (7)       | 23 (7)   |
| Alkylator-based‡                       | 96 (56)                   | 104 (60)     | 200 (58) |
| Rituximab-based                        | 1 (1)                     | 0 (0)        | 1 (1)    |
| Glucocorticoid                         | 54 (31)                   | 48 (28)      | 102 (29) |

FL, follicular lymphoma; SLL, small lymphocytic lymphoma; MZL, marginal zone lymphoma.

*One patient with more than one anti-cancer therapy has been counted under both treatment categories.
†Data are based on the electronic case report form (eCRF) database.
‡Alkylator-based therapies also include patients treated with prior bendamustine.
deaths and deaths during the study; 20% of deaths during the study and 2% of deaths during treatment in the combination arm and 15% and 5%, respectively, in the monotherapy arm were due to the disease under study (Table II).

**Safety**

During the study, 96% of patients in the combination arm and 99% in the monotherapy arm reported at least one AE of which 84% and 93%, respectively, were related to the study drug. Overall, 73% of patients in the combination arm and 80% in the monotherapy arm experienced a ≥ grade 3 AE, of which 64% and 68% respectively were related to study treatment. Serious AEs were observed in 42% and 49% of patients, in the combination and monotherapy arm respectively; and in 22% and 30% of the patients, these SAEs were due to the study drug (Table III). The most common AEs (>1% in each arm) resulting in permanent discontinuation of study drug in the combination and monotherapy arm respectively were neutropenia (6% each), thrombocytopenia (2% vs 6%), anaemia (<1% vs 2%) and leukopenia (2% vs none). Drug-related AEs observed frequently in the combination and monotherapy treatment groups were nausea (34% and 54%), neutropenia (37% and 44%) and fatigue (20% and 31%) respectively. The duration (in days) from start of treatment to first occurrence of AE has been summarized in Table IV.

**Discussion**

COMPLEMENT A + B evaluated whether the combination of ofatumumab and bendamustine improved outcomes as compared to bendamustine alone in patients refractory to a prior rituximab-based therapy. The primary end-point, PFS, evaluated at 217 events was not statistically significantly different between the two treatment groups. These results were contrary to those observed in the GADOLIN study, which evaluated the combination of obinutuzumab and bendamustine in patients with rituximab-refractory iNHL. Results of the updated GADOLIN study demonstrated a significantly longer PFS with the combination compared to bendamustine alone (25.8 months vs 14.1 months, HR = 0.57; P < 0.001), and subsequently demonstrated an OS benefit for the combination as compared to bendamustine alone (OS events: 25.5% vs 34.9%, HR = 0.67; P = 0.027) in line with its primary analysis.32,33 The
difference in outcomes observed in our study versus GADO-LIN may be due to several reasons.

Firstly, patients who received combination therapy in our study received only four additional monthly doses of ofatumumab as compared to those in the combination arm of the GADOLIN study who were treated with obinutuzumab for up to two years following completion of the bendamustine-containing cycles. Although the impact of maintenance therapy with anti-CD20 antibodies remains debated, studies in both treatment-naive and relapsed patients have demonstrated longer PFS but not OS with prolonged maintenance therapy.\(^7,34–36\) In the GADOLIN study, the PFS curves for obinutuzumab and bendamustine versus bendamustine alone appear to separate after six months suggesting that the true

![Kaplan–Meier estimates of IRC-assessed progression-free survival (PFS). The vertical axis represents the estimated rates of PFS. The number of patients at risk at each point is provided below in the table. (A) In the intent-to-treat population. (B) In patients with follicular lymphoma. OFA, ofatumumab; Benda, bendamustine. [Colour figure can be viewed at wileyonlinelibrary.com]](image-url)
Fig 3. Forest plot for subgroup analysis [age, sex, race, Follicular Lymphoma International Prognostic Index-1 (FLIPI-1), FLIPI-2, Eastern Cooperative Oncology Group (ECOG), disease type, prior rituximab status and prior bendamustine status] of progression-free survival. [Colour figure can be viewed at wileyonlinelibrary.com]
The effect of obinutuzumab was potentially a result of the prolonged maintenance phase. Therefore, it is possible that with a longer maintenance phase, a similar result would have been observed with ofatumumab. Secondly, the differences in the results from the two studies could be attributed to the differences in patient population and the underlying sub-type of iNHL. Thirdly, it is also possible that the different mechanisms of action (MOA) of ofatumumab, a type I anti-CD20 monoclonal antibody and obinutuzumab, a type II anti-CD20 monoclonal antibody, may have played a role in the discrepant study outcomes. In preclinical studies, ofatumumab has been shown to cause clustering of CD20 on the cell surface, induce complement-dependent cytotoxicity (CDC) by engaging the complement component 1q (C1q),
and induce antibody-dependent cellular cytotoxicity (ADCC), but not directly trigger apoptosis. Instead, obinutuzumab’s MOA is through directly inducing apoptosis and ADCC with decreased CDC. The safety profile for ofatumumab in this study was consistent with prior experience from other studies and remains acceptable. There were no new safety signals identified.

There are some limitations to our study. The single-agent bendamustine dose of 120 mg/m² has been associated with higher toxicity and may have contributed to the higher rates of treatment discontinuations as well as ≥grade 3 infections in the monotherapy arm; we chose this dose as it was FDA-approved, and a similar dose to what was used for single-agent bendamustine in the GADOLIN trial. The median number of prior rituximab-containing regimens was only one (1–8), and the median time since diagnosis was very

Table II. Summary of on-treatment deaths.

|                      | Ofatumumab + bendamustine (n = 172) | Bendamustine (n = 170) |
|----------------------|------------------------------------|------------------------|
| Died, n (%)          | FL  | MZL  | Other | Total | FL  | MZL  | Other | Total |
| Primary cause of death, n (%)|      |      |       |       |      |      |       |       |
| Acute myocardial infarction | 8 (5) | 1 (<1) | 3 (2) | 12 (7) | 9 (5) | 3 (2) | 3 (2) | 15 (9) |
| Adenocarcinoma        | 0    | 0    | 0     | 0     | 1 (<1) | 0    | 0     | 0     |
| Cardiopulmonary arrest| 1 (<1) | 0    | 0     | 1 (<1) | 0    | 0    | 0     | 0     |
| Disease under study   | 0    | 1 (<1) | 2 (1) | 3 (2) | 6 (4) | 1 (<1) | 2 (1) | 9 (5) |
| Failure to thrive     | 1 (<1) | 0    | 0     | 1 (<1) | 0    | 0    | 0     | 0     |
| Renal failure not related study medication | 0    | 0    | 0     | 0     | 1 (<1) | 0    | 0     | 1 (<1) |
| Rupture of aneurysma abdominalis | 1 (<1) | 0    | 0     | 1 (<1) | 0    | 0    | 0     | 0     |
| SAE not related to IP | 0    | 0    | 1 (<1) | 1 (<1) | 0    | 0    | 0     | 0     |
| SAE not related to study medication | 0    | 0    | 0     | 0     | 1 (<1) | 0    | 1 (<1) | 1 (<1) |
| SAE related to prior anthracycline induced cardiac toxicity | 1 (<1) | 0    | 0     | 1 (<1) | 0    | 0    | 0     | 0     |
| Septic shock          | 1 (<1) | 0    | 0     | 1 (<1) | 0    | 0    | 0     | 0     |
| Worsening of general conditions | 0    | 0    | 0     | 0     | 0     | 1 (<1) | 0    | 1 (<1) |

FL, follicular lymphoma; IP, investigational procedure; MZL, marginal zone lymphoma; SAE, serious adverse events.

Table III. Adverse events, ≥Grade 3 adverse events and serious adverse events irrespective of relation to study drug.

| Preferred term, n (%) | Ofatumumab + bendamustine (n = 172) | Bendamustine (n = 170) |
|-----------------------|-------------------------------------|------------------------|
| AEs (>25% of patients) | Any event 165 (96) 169 (99) | Any event 169 (99) |
|                       | Nausea 62 (36) 95 (56) | Nausea 95 (56) |
|                       | Neutropenia 66 (38) 78 (46) | Neutropenia 78 (46) |
|                       | Fatigue 42 (24) 59 (35) | Fatigue 59 (35) |
|                       | Anaemia 31 (18) 54 (32) | Anaemia 54 (32) |
|                       | Pyrexia 35 (20) 47 (28) | Pyrexia 47 (28) |
|                       | Thrombocytopenia 30 (17) 49 (29) | Thrombocytopenia 49 (29) |
|                       | Decreased appetite 24 (14) 45 (26) | Decreased appetite 45 (26) |

≥Grade 3 AEs (≥5% of patients)

| Preferred term, n (%) | Ofatumumab + bendamustine (n = 172) | Bendamustine (n = 170) |
|-----------------------|-------------------------------------|------------------------|
| Any event 126 (73) 136 (80) | Any event 136 (80) |
| Neutropenia 61 (35) 70 (41) | Neutropenia 70 (41) |
| Anaemia 13 (8) 25 (15) | Anaemia 25 (15) |
| Leukopenia 16 (9) 13 (8) | Leukopenia 13 (8) |
| Thrombocytopenia 9 (5) 32 (19) | Thrombocytopenia 32 (19) |
| Neutrophil count decreased 11 (6) 12 (7) | Neutrophil count decreased 12 (7) |
| Febrile neutropenia 12 (7) 7 (4) | Febrile neutropenia 7 (4) |
| Fatigue 6 (3) 13 (8) | Fatigue 13 (8) |
| Pneumonia 9 (5) 11 (6) | Pneumonia 11 (6) |
| Lymphopenia 10 (6) 9 (5) | Lymphopenia 9 (5) |
| Serious AEs (≥5% of patients) | Any event 72 (42) 84 (49) | Any event 84 (49) |
| Pneumonia 10 (6) 14 (8) | Pneumonia 14 (8) |
| Anaemia 2 (1) 10 (6) | Anaemia 10 (6) |
| Pyrexia 7 (4) 9 (5) | Pyrexia 9 (5) |
| Febrile neutropenia 8 (5) 5 (3) | Febrile neutropenia 5 (3) |
| Neutropenia 6 (3) 8 (5) | Neutropenia 8 (5) |

AEs, adverse events; SAEs, serious adverse events.

Table IV. Summary of duration (in days) from treatment start to first occurrence of adverse event by treatment.

| Preferred term, n (%) | Ofatumumab + bendamustine (n = 172) | Bendamustine (n = 170) |
|-----------------------|-------------------------------------|------------------------|
| AEs (>25% of patients), median days | Any event 165 (96) 169 (99) | Any event 169 (99) |
|                       | Nausea 62 (36) 95 (56) | Nausea 95 (56) |
|                       | Neutropenia 66 (38) 78 (46) | Neutropenia 78 (46) |
|                       | Fatigue 42 (24) 59 (35) | Fatigue 59 (35) |
|                       | Anaemia 31 (18) 54 (32) | Anaemia 54 (32) |
|                       | Pyrexia 35 (20) 47 (28) | Pyrexia 47 (28) |
|                       | Thrombocytopenia 30 (17) 49 (29) | Thrombocytopenia 49 (29) |
|                       | Decreased appetite 24 (14) 45 (26) | Decreased appetite 45 (26) |

and induce antibody-dependent cellular cytotoxicity (ADCC), but not directly trigger apoptosis. Instead, obinutuzumab’s MOA is through directly inducing apoptosis and ADCC with decreased CDC. The safety profile for ofatumumab in this study was consistent with prior experience from other studies and remains acceptable. There were no new safety signals identified.

There are some limitations to our study. The single-agent bendamustine dose of 120 mg/m² has been associated with higher toxicity and may have contributed to the higher rates of treatment discontinuations as well as ≥grade 3 infections in the monotherapy arm; we chose this dose as it was FDA-approved, and a similar dose to what was used for single-agent bendamustine in the GADOLIN trial. The median number of prior rituximab-containing regimens was only one (1–8), and the median time since diagnosis was very

© 2021 The Authors. *British Journal of Haematology* published by British Society for Haematology and John Wiley & Sons Ltd. *British Journal of Haematology*, 2021, 193, 1123–1133
short (2-7 years). Both suggest that patients were exposed to first-line therapy for a short period of time prior to entering our study, and patients may not have received optimal treatment with rituximab prior to being judged refractory as only three cycles of combination therapy or four infusions of rituximab monotherapy were required for study enrollment. However, this also suggests a significant number of patients enrolled in our study may have had early disease progression after initial chemo-immunotherapy. Unfortunately, we are not able to determine the exact number of these patients due to limitations in data acquisition.

In summary, combining ofatumumab and bendamustine did not show any significant improvement in the PFS when compared with bendamustine alone in patients with iNHL who were unresponsive to prior rituximab-based therapy. These findings are in contrast to the GADOLIN study, which showed that obinutuzumab in combination with bendamustine significantly improved the clinical outcomes compared to bendamustine alone in patients with rituximab-refractory iNHL. The difference in the outcome could be due to multiple factors including duration of maintenance therapy, and a difference in the MOA of the anti-CD20 antibodies.

Acknowledgements
We thank patients and their families, investigators and staff from all the participating sites. We thank Amrita Dutta, PhD and Satrupa Das, PhD of Novartis Healthcare Pvt. Ltd., Hyderabad, India for providing medical editorial assistance with this manuscript. Open Access funding enabled and organized by Projekt DEAL.

Conflicts of interest
MJR reports receiving honoraria from Celgene, Amgen, Astellas, Eisai, Gilead, Janssen, Mundipharma, Roche and Symbio; fees for Advisory Board from Amgen, Gilead, Janssen, Mundipharma and Roche; research funding from Mundipharma and Roche; AJ reports receiving consultancy fees from Janssen, Abbvie, Amgen and Roche; for Speaker’s Bureau Janssen, Abbvie, Sanofi-Genzyme, Amgen and Roche; fees for Advisory Board from Abbvie, Roche and Novartis; DM reports receiving honoraria from Roche, Lundbeck, Amgen, Gilead, Seattle Genetics, Janssen and Abbvie; JWF reports receiving honoraria from Bayer; DMD reports honoraria for Advisory Board from Roche, Amgen, Gilead, Lundbeck, Seattle Genetics, Janssen and Abbvie; JD, JL and NL are employees of Novartis; MI is an employee of Novartis and holds equity ownership in Novartis; MK and JZ have no financial relationships to disclose.

Author contributions
MJR has contributed to the conception and design, enrolled patients, and has collected and interpreted data. JWF has contributed to the conception and design, and interpretation. AJ, DMcD, M-KK and JMZ have enrolled patients, contributed to data collection, conduct of the study and the interpretation of the data. JD and MI have contributed to conception, design, data interpretation and conduct of the study. JL has contributed to data collection, interpretation and conduct of the study. All the authors have critically reviewed and approved the manuscript.

Funding
This work was supported by research funding from Novartis Pharma AG, Basel, Switzerland.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
2. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed June 25, 2020.
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835–49.
4. Rummel M, Kaiser U, Balser C, Stauh M, Brugger W, Welslau M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57–66.
5. See ZN, Allsup D. The use of ofatumumab in the treatment of B-cell malignancies. Future Oncol. 2017;13(29):2611–28.
6. Sehn LH. Introduction to a review series: the paradox of indolent B-cell lymphoma. Blood. 2016;127(17):2045–6.
7. Hainsworth JD, Litchy S, Barris HA, Scullin DC, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(20):4261–7.
8. Tageja N. Bendamustine: safety and efficacy in the management of indolent non-Hodgkin’s lymphoma. Clin Med Insights Oncol. 2011;5:145–56.
9. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmitz R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–32.
10. MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016;23(6):407–17.
11. Cracman MS, Korynya A, Mehta A, Stewart C, Donohue K, Blumenson L, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23(4):694–704.
12. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.
13. Flinn IW, Thompson DS, Bocca RV, Miletello G, Lipman A, Flora D, et al. Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. Br J Haematol. 2018;180(3):365–73.
14. Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egede M, et al. Idelalisib or placebo in combination with bendamustine and
rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2017;18(3):297–311.

15. Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2016;27 (suppl 5):v83–90.

16. Casulo C, Byrick M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. *J Clin Oncol*. 2015;33(23):2516–22.

17. Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, et al. Recommendations for clinical trial development in follicular lymphoma. *J Natl Cancer Inst*. 2016;109(3):djw255.

18. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. *Blood*. 2012;119(16):3698–704.

19. Beneckou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. *Curr Opin Oncol*. 2017;29(6):455–9.

20. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. *Cancer*. 2010;116(1):106–14.

21. Friedberg JW, Cohen P, Chen L, Robinson KS, Foreo-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. *J Clin Oncol*. 2008;26(2):204–10.

22. Rummel MJ, Al-Batran SE, Kim S-Z, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. *J Clin Oncol*. 2005;23(15):3385–9.

23. Hagenbeek A, Gadeberg O, Johnson P, Mäller Pedersen L, Walewski J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. *Blood*. 2008;111(12):3486–95.

24. Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadryov K, et al. Ofatumumab plus ifosfamide and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. *Leuk Lymphoma*. 2017;58(5):1084–93.

25. Hillen N, Robak T, Jansens A, Babu KG, Klaczko J, Grossci S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. *Lancet*. 2015;385 (9980):1873–73.

26. Collins-Burrow B, Santos ES. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. *Expert Rev Anticancer Ther*. 2007;7 (3):257–73.

27. Ghielmini M, Hsu Schmitz S-F, Cogliatti SB, Pichett G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood*. 2004;103(12):4416–23.

28. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, part 1. *Ann J Health Syst Pharm*. 2003;60(13):1531–48.

29. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol*. 2010;28(10):1749–55.

30. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol*. 2007;25(5):579–86.

31. https://www.cytel.com. East 6.4 insert.pdf (cytel.com). Accessed on April 25, 2021.

32. Cheson BD, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. *J Clin Oncol*. 2018;36(22):2259–66.

33. Sehn LH, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet*. 2016;378(9781):1081–93.

34. van Oers MHI, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. *J Clin Oncol*. 2010;28(17):2853–8.

35. Kolibaba KS, Shiveleband M, Kingsley EC, Moesi MM, Richards D, Sharma NP, et al. Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin’s lymphoma after prior rituximab. *Blood*. 2017;130(Suppl 1):1500.

36. Zhang L, Ghielmini M, Cheson BD, Ujiani C. Pros and cons of rituximab maintenance in follicular lymphoma. *Cancer Treat Rev*. 2017;58:34–40.

37. Barth MJ, Hernandez-Flizalituri FF, Mavis C, Tsai P-C, Gibbs JF, Deeb G, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. *Br J Haematol*. 2012;156(4):490–8.

38. Bleeker WK, Munk ME, Mackus WJ, van den Brakel HN, Pluyter M, Glennie MJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. *Br J Haematol*. 2008;140(3):303–12.

39. Teeling JL, Mackus WJ, Wiegman LJIM, van den Brakel HJN, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. *J Immunol*. 2006;177 (1):362–71.

40. Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. *Adv Ther*. 2017;34 (2):324–56.

41. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf. Accessed on August 24, 2018.